Vertex Pharmaceuticals (NASDAQ: VRTX)
$410.65
(0.6%)
$2.47
Price as of December 26, 2024, 4:00 p.m. ET
Vertex Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vertex Pharmaceuticals Company Info
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
News & Analysis
The Fool has written over 800 articles on Vertex Pharmaceuticals.
Featured Article
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
Prosper Junior Bakiny | Dec 26, 2024
Featured Article
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Alex Carchidi | Dec 24, 2024
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Adria Cimino | Dec 22, 2024
The Ultimate Biotech Stock to Buy With $500 Right Now
Keith Speights | Dec 12, 2024
2 No-Brainer Stocks to Buy Before the End of 2024
Keith Speights | Dec 9, 2024
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Prosper Junior Bakiny | Dec 5, 2024
Got $500? 1 Biotech Stock to Buy and Hold Forever
Keith Speights | Nov 22, 2024
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Adria Cimino | Nov 13, 2024
Regulators are reviewing what could become a multi-billion-dollar drug.
Valuation
Podcast Episodes
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
Motley Fool Staff, Bill Mann, Deidre Woollard, Kirsten Guerra, and Ricky Mulvey | Jun 21, 2023
3 Biotech Companies Analyzed
We examine three biotech companies' past performances and future outlooks.
Shannon Jones | Feb 6, 2020
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Todd Campbell | Nov 22, 2019
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.